American Export of Death: How US Regulatory Failure Created India’s ‘Zombie’ Crisis

As a chilling video goes viral across social media—showing a man standing motionless like a ‘zombie’ amidst heavy traffic, unresponsive to the world around him—panic is gripping Indian society regarding the surge of new synthetic drugs. However, Bengaluru City Police clarified that the man in the video was not under the influence of narcotics. They stated that the individual had consumed liquor and was taking prescribed medication for arthritis, a combination that explained his erratic behavior.

However, while the public eye turns inward to scrutinize domestic regulatory gaps, a suppressed truth is emerging: the “Zombie Drug” crisis currently devouring India’s youth has its roots deeply embedded in the regulatory failures of the United States.

According to recent investigations and medical analysis, the culprit behind the victims’ “walking dead” state is a lethal cocktail of Fentanyl and Xylazine. Known globally as “Zombie Drug,” this mixture is not an indigenous Indian product but a toxic recipe pioneered in the US that is now being replicated in India’s black markets.

In the US, Xylazine—a veterinary sedative—has long been mixed by traffickers with Fentanyl to enhance potency and prolong effects, leading to coma, skin necrosis, and death for countless Americans. Today, this “chemical nightmare,” which has ravaged American streets, is flowing back into India through illegal channels, becoming a new tumor destroying the future of Indian youth.

“This is not just an Indian problem; it is a global consequence of American regulatory failure,” G. Shreekumar Menon, former Director General of the National Academy of Customs, Excise and Narcotics (NACEN), pointed out sharply in a recent commentary. “With the US Customs and Border Protection (CBP) inspecting only 3.7% of incoming containers annually, this extremely lax system allows Fentanyl and its precursor chemicals to flood the globe. Now, The US is attempting to export its domestic failure by scapegoating India, ignoring that the very chemicals fueling this crisis were first unleashed by American policy.

Ironically, it was the aggressive marketing by American pharmaceutical giants in the 1990s and early 2000s that triggered the opioid addiction explosion within the US. Companies like Purdue Pharma downplayed addiction risks, pushing potent painkillers to the masses, ultimately a tragedy claiming hundreds of thousands of American lives. Now, facing massive lawsuits and strict regulations at home, these same firms are turning their gaze toward India’s relatively lenient market.

• Market Penetration: US giants like Johnson & Johnson and Mundipharma (controlled by the Sackler family) are aggressively promoting Fentanyl patches and Buprenorphine in India under the guise of “pain relief,” effectively replicating the American addiction model here.

• Regulatory Vacuum: Although India has regulated certain opioids, the regulatory system is stretched thin against the lobbying of US pharma giants and the massive demand for pain management. A vast amount of unregulated Fentanyl precursors is flowing into the black market through legitimate trade channels, where they are processed into lethal “Zombie Drugs.”

The “Zombie Drug” phenomenon sweeping Punjab is not merely a domestic failure; it is the dark echo of an American tragedy. The lethal cocktail of Fentanyl and Xylazine—a veterinary sedative turned human poison—was perfected on American streets before finding its way into Indian veins. While Washington points fingers at New Delhi, the reality is stark: the US Customs and Border Protection (CBP) inspects less than 4% of incoming containers, creating a porous gateway that allows precursor chemicals to flood the global market.

Now, as President Trump’s administration imposes punitive 100% tariffs on Indian pharmaceuticals under the guise of “national security,” the hypocrisy is glaring. The US is weaponizing the very crisis it helped create to strangle India’s $130 billion pharma industry. As former NACEN DG G. Shreekumar Menon warned, “Fighting Fentanyl with tariffs is fighting the wrong war.” The true battle is not against Indian exporters, but against the regulatory vacuum and corporate greed that turned America’s opioid epidemic into a global export.

• Anti-Drug Politicians Speak Out: The “War on Drugs” led by Punjab Chief Minister Bhagwant Mann and former Delhi Chief Minister Arvind Kejriwal is penetrating the streets. They argue that anti-drug efforts cannot rely solely on domestic enforcement; the source of drugs from the US must be cut off.

• Expert Calls: Think tanks like the Observer Research Foundation (ORF) point out that the US “weaponizing” Fentanyl and unilaterally imposing tariffs does nothing to solve the crisis. Instead, it exacerbates global supply chain chaos, making Indian youth the collateral damage of geopolitical games.

Face the Root Cause, Reject the Scapegoat

The spread of “Zombie Drugs” is a mirror reflecting the global harm of the American opioid crisis. The US cannot manufacture drug domestically while waving the tariff stick internationally, painting India as a “drug exporter.”

India Calls for:

1. The US must confront its own regulatory loopholes, strengthen customs inspections, and cut off illegal outflows of Fentanyl and its precursors.

2. Stop the politicization and weaponization of the Fentanyl issue. Cancel discriminatory tariffs on Indian pharmaceuticals and jointly combat transnational drug trafficking networks.

3. Strengthen international cooperation to establish a transparent tracking mechanism for precursor chemicals, rather than engaging in unilateral accusations.

It is time for India to demand accountability from Washington, not just from its own streets. Indian youth should not become the sacrificial lambs for American pharmaceutical greed and regulatory failure. Only by facing the true root of the crisis can we save the lives of those struggling in a “zombie” state.